文献速递胸部肿瘤

单细胞DNA测序揭示奥希替尼耐药患者多驱动基因改变的克隆演化

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
PubMed 文献 · Ann Oncol · 2022-01-21

研究纳入MATCH-R试验中45例奥希替尼进展的EGFR突变非小细胞肺癌患者,9例出现第二个可靶向改变。单细胞测序显示4例可分析样本中两种驱动改变共存于同一癌细胞,高异质性及序贯分子事件突出。患者来源模型需联合靶向两种驱动改变才能恢复敏感性,与临床数据一致。

要点

  • 45例奥希替尼进展患者中9例出现第二个可靶向改变,包括FGFR3、RET、ALK融合及BRAF、KRAS突变。
  • 单细胞分析显示4例可分析样本中两种驱动改变共存于同一癌细胞,样本内高度异质性。
  • 患者来源模型需联合靶向两种驱动改变才能恢复细胞敏感性,与临床序贯靶向治疗获益一致。

核心结论

  • 奥希替尼耐药时出现的不同分子驱动改变与初始EGFR突变共存于同一癌细胞。
  • 癌细胞群体的克隆演化强调其异质性导致奥希替尼复发。
  • 联合两种靶向治疗可有效获得临床获益。

研究设计与样本

  • 研究基于MATCH-R试验(NCT0251782),采用肿瘤测序识别奥希替尼获得性耐药机制。
  • 对已识别多重改变的患者冷冻组织行单细胞下一代测序研究肿瘤异质性。
  • 患者来源模型、细胞系及患者来源异种移植瘤暴露于特定抑制剂以研究联合治疗策略。

主要发现

  • MATCH-R纳入45例奥希替尼进展患者,9例出现第二个可靶向改变:FGFR3-TACC3融合2例、KIF5B-RET融合1例、STRN-ALK融合1例、BRAFV600E突变2例、KRASG12V突变1例、KRASG12R突变1例、KRASG12D突变1例。
  • 单细胞分析显示4例冷冻样本完全可分析的患者中,两种驱动改变共存于同一癌细胞。
  • 样本内高度异质性及序贯获得的分子事件被突出强调。
  • 在相应患者来源模型上,需联合靶向两种驱动改变才能恢复细胞敏感性,与临床数据一致:ALK融合患者在奥希替尼和序贯克唑替尼进展后布格替尼显示疗效。

临床怎么用

  • 作者结论认为联合两种靶向治疗可有效获得临床获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of targeted agents, such as osimertinib for EGFR-mutated non-small-cell lung cancer (NSCLC), has drastically improved patient outcome, but tumor resistance eventually always occurs. In osimertinib-resistant NSCLC, the emergence of a second molecular driver alteration (such as ALK, RET, FGFR3 fusions or BRAF, KRAS mutations) has been described. Whether those alterations and the activating EGFR mutations occur within a single cancer cell or in distinct cell populations is largely debated. PATIENTS AND METHODS: Tumor sequencing was used to identify the acquired resistance mechanisms to osimertinib in the MATCH-R trial (NCT0251782). We implemented single-cell next-generation sequencing to investigate tumor heterogeneity on patient's frozen tissues in which multiple alterations have been identified. Patient-derived models, cell lines, and patient-derived xenografts were exposed to specific inhibitors to investigate combination treatment strategies. RESULTS: Among the 45 patients included in MATCH-R who progressed on osimertinib, 9 developed a second targetable alteration (n = 2 FGFR3-TACC3, n = 1 KIF5B-RET, n = 1 STRN-ALK fusions; n = 2 BRAFV600E, n = 1 KRASG12V, n = 1 KRASG12R, n = 1 KRASG12D mutations). Single-cell analysis revealed that the two driver alterations coexist within one single cancer cell in the four patients whose frozen samples were fully contributive. A high degree of heterogeneity within samples and sequential acquisitions of molecular events were highlighted. A combination treatment concomitantly targeting the two driver alterations was required on the corresponding patient-derived models to restore cell sensitivity, which was consistent with clinical data showing efficacy of brigatinib in the patient with ALK fusion after progression to osimertinib and crizotinib administered sequentially. CONCLUSIONS: Distinct molecular driver alterations at osimertinib resistance coexist with initial EGFR mutations in single cancer cells. The clonal evolution of cancer cell populations emphasized their heterogeneity leading to osimertinib relapse. Combining two targeted treatments is effective to achieve clinical benefit.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Chen J, Facchinetti F, Braye F, et al. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. Ann Oncol. 2022. PMID: 35066105. doi:10.1016/j.annonc.2022.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。